Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Pasireotide

Criteria

Inclusion Criteria:

• gonadotroph adenoma

Exclusion Criteria:

• visual impairment attributable to the adenoma

• radiation therapy

• active gallbladder disease

• uncontrolled diabetes